Cellular and cytokine responses of the human central nervous system to intracranial administration of tumor necrosis factor α for the treatment of malignant gliomas

1993 ◽  
Vol 36 (4) ◽  
pp. 251-259 ◽  
Author(s):  
Mitsuhiro Tada ◽  
Yutaka Sawamura ◽  
Shirou Sakuma ◽  
Kazuo Suzuki ◽  
Hidemi Ohta ◽  
...  
1992 ◽  
Vol 77 (1) ◽  
pp. 78-83 ◽  
Author(s):  
Jun Yoshida ◽  
Toshihiko Wakabayashi ◽  
Masaaki Mizuno ◽  
Kenichiro Sugita ◽  
Tazuka Yoshida ◽  
...  

✓ Recombinant human tumor necrosis factor-α was administered intra-arterially to treat 20 cases of malignant gliomas, mostly progressive or recurrent. The optimum dosage was determined to be 1 × 105 U/sq m/day. Among the 10 evaluable patients treated at this dosage, two responded (one completely and one partially), resulting in a 20% response rate. Side effects were mild and easily controllable. Improvement of neurological symptoms was noted in 47% of the patients a few days after treatment, even when computerized tomography showed no tumor regression. This might have been due to the pleiotypic biological activity of tumor necrosis factor-α. Neuroradiographic observations revealed narrowing of the tumor-feeding artery, a decrease in tumor staining ability, and necrosis in the central part of a tumor. The authors suggest that intra-arterial administration of tumor necrosis factor-α may be an effective treatment for malignant glioma, including recurrent cases.


1994 ◽  
Vol 34 (4) ◽  
pp. 216-220 ◽  
Author(s):  
Toshiki YAMASAKI ◽  
Kouzo MORITAKE ◽  
Jonathan T. PAINE ◽  
Minoru FUKUDA ◽  
Fumihito OHTA ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document